Podcasts

E-Books

Videos

Articles

Business & Practice

Skylar Jeremias is the Managing Editor for The Center for Biosimilars and The American Journal of Managed Care (AJMC).

There has been an outpouring of advocacy tugging biosimilars into the marketplace, and market share of these lower-cost drugs has increased.
 

Biosimilars Gain Market Share and Advocates Get Aboard

Tony Hagen is senior managing editor for The Center for Biosimilars

Defining biosimilar use in the United States as "sluggish," Juliana Reed, MS, said employers have to get involved.

Pfizer Expert Urges Employers to Get Proactive on Biosimilars

Dismayed at the low biosimilar uptake and the lost savings, large employers are taking matters into their own hands.
 

Disney Official, Others Talk About Switch to Biosimilars

Opening the door to biosimilar competition starts with breaking down the patent barrier, says Christine Simmon, JD.

Christine Simmon and the Fight for Patent Reform

Now that Polpharma Biologics has fully integrated Bioceros into its brand, the company hopes to become one of the world’s leading biologics manufacturers.

Polpharma Biologics: The Polish Biosimilar Powerhouse

United States Pharmacopeia (USP), the FDA, and others deliver constructive critique on how India can bolster quality in its biopharmaceutical industry.

USP Panel Recommends Quality Upgrade for India's Biopharmaceutical Industry

Samsung Bioepis makes a move into the promising Brazilian market for biosimilars, which data suggest is one of the fastest-growing biosimilars markets among emerging nations.

Samsung Bioepis Enters Breast and Gastric Market in Brazil

Nancy J. Globus, PharmD, is Vice President of Regulatory Affairs for the Accreditation Council for Medical Affairs, based in Oradell, New Jersey. Nancy focuses on helping the industry build error prevention into products by evaluating proposed names and labels prior to regulatory approval. In her 20-year medication safety career, she has reviewed thousands of names for submission to FDA, European Medicines Agency, and Health Canada. In addition to medication safety, she is passionate about patient advocacy and community pharmacy. You can find her at www.medicalaffairsspecialist.org/approve or on Twitter @MedSafetyGal.

Alphabet Soup: The Story Behind Biosimilar Nonproprietary Name Suffixes

With a sizable milestone payment from its partner Mylan, Revance has stepped up efforts to launch contenders in the Botox space.

Revance Moves Forward With 2 Botox Competitors

Originator biologics should be monitored as closely as biosimilars, according to Gary Lyman, MD, MPH, of the Hutchinson Institute for Cancer Outcomes Research.

Business